QuickView: TRT under FDA spotlight
A joint panel of two FDA advisory committees voted in September to modify the labelling of TRT products to curtail usage when clinical benefit may not be definitive. While it is unclear how the FDA will respond, we believe that end-user demand for TRT will largely persist and that Natesto’s novel delivery should generate interest when launched in H115.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.